健康元：健康元药业集团股份有限公司2022年第三季度报告（英文版）.PDF

《健康元：健康元药业集团股份有限公司2022年第三季度报告（英文版）.PDF》由会员分享，可在线阅读，更多相关《健康元：健康元药业集团股份有限公司2022年第三季度报告（英文版）.PDF（13页珍藏版）》请在淘文阁 - 分享文档赚钱的网站上搜索。

1、Joincare Pharmaceutical Group Industry Co.,Ltd.2022 Third Quarterly Report 1/13 Stock Code:600380 Stock Short Name:健康元 Joincare Pharmaceutical Group Industry Co.,Ltd.2022 Third Quarterly Report The Board of Directors and all Directors of the Company hereby warrant that there are no false representat

2、ions,misleading statements or material omissions contained in this announcement and accept legal responsibility for the truthfulness,accuracy and completeness of the contents hereof.IMPORTANT NOTICE:The Board of Directors,the Board of Supervisors and Directors,Supervisors and senior management of th

3、e Company hereby warrant the truthfulness,accuracy and completeness of the contents of this quarterly report,and that there are no false representations,misleading statements or material omissions contained herein,and severally and jointly accept legal responsibility.The person-in-charge of the Comp

4、any,the person-in-charge of accounting work and the person-in-charge of the accounting department(the head of the accounting department)hereby warrant the truthfulness,accuracy and completeness of the financial information contained in this quarterly report.Whether the third quarterly financial stat

5、ements are audited.Yes No I.MAJOR FINANCIAL DATA(I)Major Accounting Date and Financial Indicators Unit:Yuan Currency:RMB Item For the Reporting Period YoY change(%)From the beginning of the year to the end of the Reporting Period YoY change(%)Revenue 4,447,021,452.61 8.51 13,011,966,738.16 9.04 Join

6、care Pharmaceutical Group Industry Co.,Ltd.2022 Third Quarterly Report 2/13 Net profit attributable to shareholders of the listed company 325,293,433.73 1.23 1,126,561,953.23 11.69 Net profit attributable to shareholders of the listed company after deduction of extraordinary gains and losses 312,360

7、,089.27-2.90 1,116,354,521.30 21.40 Net cash flow from operating activities N/A N/A 2,608,992,532.97 60.93 Basic earnings per share(RMB/share)0.1748 6.61 0.5983 16.09 Diluted earnings per share(RMB/share)0.1739 6.19 0.5971 16.13 Weighted average return on net assets(%)2.74 Decreased by 0.11 percenta

8、ge points 9.39 Increased by 0.50 percentage points As at the end of the Reporting Period As at the end of the previous year YoY change(%)Total assets 34,713,695,364.54 31,103,900,389.29 11.61 Owners equity attributable to shareholders of the listed company 12,900,492,209.56 11,820,293,656.69 9.14 No

9、tes:1.The“Reporting Period”represents the 3-month period from the beginning to the end of this quarter,the same below.2.From July to September 2022,the Company realized net profit attributable to shareholders of the parent of RMB325 million,of which Joincare excluding Livzon Pharmaceutical Group Inc

10、.(“Livzon Group”)and Livzon MAB Pharm Inc.(“Livzon MAB”)realized net profit attributable to shareholders of the parent of approximately RMB217 million,representing a YoY increase of approximately 37%,and the impact of Livzon MAB on the net profit attributable to shareholders of the parent was approx

11、imately negative RMB186 million.From January to September 2022,the Company realized net profit attributable to shareholders of the parent of RMB1,127 million,of which Joincare(excluding Livzon Group and Livzon MAB)realized net profit attributable to shareholders of the parent of approximately RMB638

12、 million,representing a YoY increase of approximately 42%,and the impact of Livzon MAB on the net profit attributable to shareholders of the parent was approximately negative RMB325 million.3.From January to September 2022,the Company realized revenue of RMB7,402 million from chemical pharmaceutical

13、s,representing a YoY increase of 7.16%,among which,RMB862 million were from respiratory formulation,representing a YoY increase of 215%;RMB1,151 million were from anti-infective products,representing a YoY increase of 9.29%;RMB2,646 million were from gastroenterology products,representing a YoY decr

14、ease of 11.60%;RMB2,092 million were from gonadotropic hormones,representing a YoY increase of 5.81%and RMB400 million were from psychiatry products,representing a YoY increase of 30.68%.The Company realized revenue of RMB4,054 million from APIs and intermediates,representing a YoY increase of 17.80

15、%.The Company realized revenue of RMB864 million from traditional Chinese medicine,representing a YoY increase of 1.28%.The Company realized revenue of RMB502 million from diagnostic reagents and equipment,representing a YoY decrease of 9.09%.The Company realized revenue of RMB83 million from health

16、 care products,representing a YoY decrease of 4.30%.Joincare Pharmaceutical Group Industry Co.,Ltd.2022 Third Quarterly Report 3/13(II)Items and Amounts of Extraordinary Gains and Losses Unit:Yuan Currency:RMB Item For the Reporting Period From the beginning of the year to the end of the Reporting P

17、eriod Gain or loss on disposal of non-current assets 1,429,336.99 5,161,222.54 Government grants recognized in profit or loss for the current period(excluding government grants that are closely related to the ordinary operating business of the Company and are provided in fixed amount or quantity con

18、tinuously according to the applicable polices and standards of the country)45,982,790.93 140,167,993.52 Gains and losses on fair value changes incurred from financial assets held for trading,derivative financial assets,financial liabilities held for trading and derivative financial liabilities,and i

19、nvestment income on disposal of financial assets held for trading,derivative financial assets,financial liabilities held for trading,derivative financial liabilities and other debt investments,except for effective hedging activities related to the ordinary operating business of the Company-14,007,79

20、8.34-112,944,327.05 Reversal of provision for impairment of accounts receivable and contract assets tested for impairment individually 0.00 158,470.77 Other non-operating income and expenses apart from the above items-6,269,628.08-8,540,320.05 Less:Effect of income tax-330,154.62 10,109,361.17 Effec

21、t of minority equity(after tax)14,531,511.66 3,686,246.63 Total 12,933,344.46 10,207,431.93 Explanations for classifying items of extraordinary gains and losses defined in the Explanatory Announcement No.1 for Public Company Information Disclosures Non-recurring Profits and Losses as items of recurr

22、ing profit or loss Applicable N/A (III)Changes in Major Accounting Data and Financial Indicators and Reasons Therefor Applicable N/A Item Change(%)Main reasons Net cash flow from operating activities 60.93 Mainly due to an increase of cash collections of sales revenues.(IV)Material Changes in Other

23、Items in Financial Statements and Financial Indicators and Reasons Therefor Joincare Pharmaceutical Group Industry Co.,Ltd.2022 Third Quarterly Report 4/13 Balance Sheet 30 September 2022 31 December 2021 Change in proportion（%）Main Reason Financial assets held for trading 121,394,233.59 184,638,344

24、.31-34.25 Primarily due to fluctuations in market value of the securities investment held.Other receivables 51,182,462.61 88,053,825.12-41.87 Mainly due to the receipt of payment during the current period.Non-current assets due within one year 38,498.84 317,381.23-87.87 Primarily due to the recovery

25、 of finance lease payments.Other current assets 28,941,853.23 83,986,214.37-65.54 Primarily due to the decrease in the amount of VAT credits as a result of the refund thereof and the prepaid income tax has transferred out.Long-term receivables 82,574.69 266,904.13-69.06 Primarily due to the recovery

26、 of finance lease payments.Financial liabilities held for trading 23,888,725.35 143,302.24 16570.17 Primarily due to fluctuations in fair value of foreign exchange forward contract Contract liabilities 85,390,395.48 234,140,702.29-63.53 Primarily due to some contract performance obligations during t

27、he current period,which satisfies the conditions for revenue recognition and results in the carrying forward of revenue.Taxes payable 356,093,489.85 270,618,183.41 31.59 Primarily due to the increase in corporate income tax payable.Non-current liabilities due within one year 19,385,099.93 91,576,066

28、.33-78.83 Mainly due to an increase of repayment of long-term borrowings.Other current liabilities 5,977,716.75 15,626,224.29-61.75 Primarily due to the decrease in pending output tax as the contract payment collected in advance in the current period meets the revenue recognition conditions and is c

29、arried forward.Long-term loans 3,028,666,590.94 826,780,252.78 266.32 Mainly due to an addition to long-term borrowings during the current period.Other comprehensive income 37,371,610.95 5,387,545.97 593.67 Mainly due to change of exchange differences on translation of statements as a result of fluc

30、tuation in exchange rate.Statement of Income January to September for 2022 January to September for 2021 Change in proportion（%）Main Reason Financial expenses-330,371,807.68-43,302,001.92 N/A Mainly due to the deposit interest during the current period is higher than last period and the Joincare Pha

31、rmaceutical Group Industry Co.,Ltd.2022 Third Quarterly Report 5/13 exchange gains arising from fluctuation in exchange rate.Income from investments(loss is indicated by“-”)48,386,584.36 69,260,277.50-30.14 Primarily due to a decrease in dividend for the current period,together with fluctuation in e

32、xchange rate and losses from settlement of the forward foreign exchange contract business.Gains from changes in fair values(loss is indicated by“-”)-86,989,533.83-18,014,545.96 N/A Primarily due to fluctuations in market value of the securities investment held.Impairment loss of assets(loss is indic

33、ated by“-”)-142,159,872.24-35,798,711.62 N/A Primarily due to the impairment provision for inventories for the current period is higher than last period.Gains from disposal of assets(loss is indicated by“-”)1,121,679.66 18,357,859.21-93.89 Mainly due to gains from transfer of land use rights during

34、last period.Cash Flow Statement January to September for 2022 January to September for 2021 Change in proportion（%）Main Reason Net cash flow from operating activities 2,608,992,532.97 1,621,169,704.58 60.93 Mainly due to an increase of cash collections of sales revenues for the current period.Net ca

35、sh flow from investing activities-886,929,197.44-1,509,334,937.50 N/A Mainly due to the combination of cash collection through selling equity and the additional investment for last period.Net cash flow from financing activities 873,841,344.96-1,783,771,890.06 N/A Mainly due to the further borrowings

36、 and capital raised(issuance of GDRs)for the current period.II.SHAREHOLDERS(I)Total Number of Holders of Ordinary Shares and Number of Holders of Preferred Shares with Restored Voting Rights and Shareholdings of Top 10 Shareholders Unit:shares Total number of holders of ordinary shares as of the end

37、 of the Reporting Period 96,795 Total number of holders of preferred shares with restored voting rights as of the end of the Reporting Period(if any)0 Shareholdings of the top 10 shareholders Name of shareholder Nature of shareholder Number of shares held Percentage(%)Number of shares held with sell

38、ing restrictions Pledge,mark or lock-up Share status Number Shenzhen Baiyeyuan Investment Co.,Ltd.(深圳市百业源投资有限公司)Domestic non-state-owned entity 878,272,753 45.56 0 Pledge 95,679,725 Hong Kong Securities Clearing Company Limited Unknown 130,019,561 6.74 0 Unknown Citibank,National Association Unknown

39、 63,825,000 3.31 0 Unknown Joincare Pharmaceutical Group Industry Co.,Ltd.2022 Third Quarterly Report 6/13 Might Seasons Limited Foreign entity 57,487,434 2.98 0 Unknown Huaxia Life Insurance Co.,Ltd.-Own fund Unknown 9,275,718 0.48 0 Unknown He Zhong Domestic natural person 7,800,024 0.40 0 Unknown

40、 Abu Dhabi Investment Authority(阿布达比投资局)Foreign entity 6,334,742 0.33 0 Unknown Joincare Pharmaceutical Group Industry Co.,Ltd.the Second Phase Ownership Scheme under Medium to Long-term Business Partner Share Ownership Scheme(健康元药业集团股份有限公司中长期事业合伙人持股计划之第二期持股计划)Others 6,275,372 0.33 0-16011 portfolio

41、 of basic endowment insurance fund Unknown 5,867,634 0.30 0 Unknown Agricultural Bank of China Limited-CSI 500 Exchange Traded Index Securities Investment Fund Unknown 5,480,994 0.28 0 Unknown Shareholdings of the top 10 shareholders without selling restrictions Name of shareholder Number of tradabl

42、e shares held without selling restrictions Class and number of shares Class of shares Number Shenzhen Baiyeyuan Investment Co.,Ltd.(深圳市百业源投资有限公司)878,272,753 Ordinary shares denominated in Renminbi 878,272,753 Hong Kong Securities Clearing Company Limited 130,019,561 Ordinary shares denominated in Re

43、nminbi 130,019,561 Citibank,National Association 63,825,000 Ordinary shares denominated in Renminbi 63,825,000 Might Seasons Limited 57,487,434 Ordinary shares denominated in Renminbi 57,487,434 Huaxia Life Insurance Co.,Ltd.-Own fund 9,275,718 Ordinary shares denominated in Renminbi 9,275,718 He Zh

44、ong 7,800,024 Ordinary shares denominated in Renminbi 7,800,024 Abu Dhabi Investment Authority(阿布达比投资局)6,334,742 Ordinary shares denominated in Renminbi 6,334,742 Joincare Pharmaceutical Group Industry Co.,Ltd.the Second Phase Ownership Scheme under Medium to Long-term Business Partner Share Ownersh

45、ip Scheme(健康元药业集团股份有限公司中长期事业合伙人持股计划之第二期持股计划)6,275,372 Ordinary shares denominated in Renminbi 6,275,372 16011 portfolio of basic endowment insurance fund 5,867,634 Ordinary shares denominated in Renminbi 5,867,634 Agricultural Bank of China Limited-CSI 500 Exchange Traded Index Securities Investment

46、 Fund 5,480,994 Ordinary shares denominated in Renminbi 5,480,994 Description of connection or acting-in-concert relationship of the above shareholders There was no connection or acting-in-concert relationship between Shenzhen Baiyeyuan Investment Co.,Ltd.,a controlling shareholder of the Company,an

47、d other shareholders;whether there is connection or acting-in-concert relationship among other shareholders is unknown Joincare Pharmaceutical Group Industry Co.,Ltd.2022 Third Quarterly Report 7/13 Description of the participation of the top 10 shareholders and the top 10 shareholders without selli

48、ng restrictions in margin financing and securities lending and refinancing business(if any)As of the end of the Reporting Period,the number of the shares lent from Shenzhen Baiyeyuan Investment Co.,Ltd.,a controlling shareholder of the Company,through participation in refinancing is 17,380,900,witho

49、ut any transfer of ownership.He Zhong,a shareholder,holds a total of 7,800,024 shares of the Company,including 800,000 shares held through ordinary securities accounts and 7,000,024 shares held through credit securities accounts.Description of the special repurchase account among the top 10 sharehol

50、ders As of the end of the Reporting Period,the special repurchase account of the Company(special securities repurchase account of Joincare Pharmaceutical Group Industry Co.,Ltd.)owned 17,459,813 shares in total,accounting for 0.91%.Note:Citibank,National Association is the depositary of the Companys